Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 176 - 200 of 14741 in total

Ceftriaxone

Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges , eyes , and inner ear . Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone...
Approved
Matched Description: … meninges[A215582], eyes[A215647], and inner ear[A215627]. ... [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the ... Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins …
Matched Mixtures name: … Hovid Ceftriaxone 1g with Lidocaine 1% ... Hovid-Ceftriaxone 0.5g with Lidocaine 1% …
Matched Products: … Ceftriaxone and Dextrose …

Mitapivat

Mitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red...
Approved
Investigational
Matched Description: … hemolytic anemia, such as sickle cell disease and alpha- and beta-thalassemia. ... the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with ... L40533] Mitapivat has also been investigated in other hereditary red blood cell disorders associated with …
Matched Categories: … Blood and Blood Forming Organs ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Copanlisib

Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated...
Approved
Investigational
Matched Description: … Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity ... against the alpha and delta isoforms. ... , that exists in different isoforms and is often overexpressed in hematological malignancies. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index …

Ceftazidime

Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis,...
Approved
Matched Description: … or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of bacterial ... [A232920, A232925, A232930] Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial ... a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and …
Matched Products: … Ceftazidime and Dextrose ... CEFTAZIDIME ALVOGEN POWDER FOR SOLUTION FOR INJECTION AND INFUSION 1G/ VIAL …

Procainamide

A derivative of procaine with less CNS action.
Approved
Matched Description: … A derivative of procaine with less CNS action. …
Matched Categories: … Benzamides and benzamide derivatives ... OCT2 Substrates with a Narrow Therapeutic Index ... MATE 1 Substrates with a Narrow Therapeutic Index ... MATE 2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …

Ixabepilone

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Description: … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Methyltestosterone

A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US.
Approved
Matched Description: … Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer ... A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement …
Matched Mixtures name: … Esterified Estrogens and Methyltestosterone ... Esterified Estrogens and Methyltestosterone ... Esterified Estrogens and Methyltestosterone …
Matched Categories: … Androgens and Estrogens ... methyltestosterone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Tetracycline

Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the...
Approved
Vet approved
Withdrawn
Matched Description: … exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and ... It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane …
Matched Mixtures name: … Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride ... Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride …
Matched Categories: … Alimentary Tract and Metabolism ... tetracycline and oleandomycin ... Ophthalmological and Otological Preparations ... lansoprazole, tetracycline and metronidazole ... Antiinfectives and Antiseptics for Local Oral Treatment …
Matched Products: … MeaStem First Aid and Antibiotic …

Niraparib

Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … [L43277] Niraparib is selective towards PARP-1 and PARP-2. ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents ... MATE 1 Substrates with a Narrow Therapeutic Index ... MATE 2 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index …

Magaldrate

Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Approved
Withdrawn
Matched Description: … Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and …
Matched Categories: … Antacids With Antiflatulents ... Alimentary Tract and Metabolism ... magaldrate and antiflatulents ... Aluminum and magnesium containing antacids …

Valproic acid

Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into...
Approved
Investigational
Matched Description: … Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in ... [A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for ... It is currently a compound of interest in the field of oncology for its anti-proliferative effects and …
Matched Categories: … UGT1A1 Substrates with a Narrow Therapeutic Index ... UGT1A3 Substrates with a Narrow Therapeutic Index ... UGT1A6 Substrates with a Narrow Therapeutic Index ... UGT1A9 Substrates with a Narrow Therapeutic Index ... UGT2B7 Substrates with a Narrow Therapeutic Index …

Erlotinib

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential ... potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with ... EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …

Darunavir

Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006. Darunavir is being...
Approved
Matched Description: … Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as [ritonavir] ... [A191682] Clinical trials are underway and are expected to conclude in August 2020.[L12066] …
Matched Categories: … darunavir and ritonavir ... darunavir and cobicistat ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... emtricitabine, tenofovir alafenamide, darunavir and cobicistat …
Matched Products: … Darunavir 600 and 800 mg …

Clofarabine

Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic...
Approved
Investigational
Matched Description: … It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. ... Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides ... OCT2 Substrates with a Narrow Therapeutic Index ... OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index …

Simethicone

Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. It has a favourable safety profile as it is not systemically absorbed. Simethicone has been in use since the 1940s but was granted FDA approval in 1952.
Approved
Matched Mixtures name: … Gelusil Antacid and Anti-gas ... Antacid Regular With Anti-gas ... Tums Chewy Bites with Gas Relief …

Curcumin

Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities . Due to these properties, curcumin has been investigated for the treatment and...
Approved
Investigational
Matched Description: … in [Curcuma xanthorrhiza oil]. ... also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and ... molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and …

Haloperidol

Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within...
Approved
Matched Description: … [F4645] It is also used off-label for the management of chorea associated with Huntington's disease and ... However, these findings contradict the findings from studies in vitro with human liver microsomes and ... [A32346] First-generation antipsychotic drugs have largely been replaced with second- and third-generation …

D-Methionine

Approved
Experimental
Investigational
Matched Mixtures name: … NUTRINEAL PD]4 Peritoneal Dialysis Solution with 1.1% Amino Acids …

Amitriptyline

Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.
Approved
Matched Mixtures name: … Perphenazine and Amitriptyline Hydrochloride ... Perphenazine and Amitriptyline Hydrochloride ... Chlordiazepoxide and Amitriptyline HCl …
Matched Categories: … amitriptyline and psycholeptics ... Tricyclics and Other Norepinephrine-reuptake Inhibitors ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index …

Baricitinib

Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … [A248405] While baricitinib was granted emergency use as a treatment for COVID-19 in combination with ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... MATE 2 Substrates with a Narrow Therapeutic Index ... OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Dasatinib

Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein...
Approved
Investigational
Matched Description: … BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the ... ) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region ... pathogenesis of CML and 15-30% of ALL cases. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index …

Bendamustine

Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine...
Approved
Investigational
Matched Description: … a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and ... Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks ... It is active against both active and quiescent cells, although the exact mechanism of action is unknown …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index …

Sodium acetate

Sodium Acetate is chemically designated CH3COONa, a hygroscopic powder very soluble in water. Sodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in buffer solutions. Medically, sodium acetate is important component as an electrolyte replenisher when given intravenously. It is mainly indicated to correct...
Approved
Investigational
Matched Description: … It can be used also in metabolic acidosis and for urine alkalinization. ... Sodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in …
Matched Mixtures name: … Plasma-Lyte 148 and dextrose ... Normosol-R and Dextrose ... Plasma-Lyte M and Dextrose …
Matched Categories: … Blood and Blood Forming Organs ... Blood Substitutes and Perfusion Solutions …

Iron sucrose

Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron...
Approved
Matched Description: … (hemodialysis or peritoneal) and those who do not require dialysis. ... Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with ... iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis …
Matched Mixtures name: … Poly-Vi-Flor with Iron …
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Displaying drugs 176 - 200 of 14741 in total